Unknown

Dataset Information

0

Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib.

ABSTRACT:

SUBMITTER: Brown JR 

PROVIDER: S-EPMC7829041 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib.

Brown Jennifer R JR   Zelenetz Andrew A   Furman Richard R   Lamanna Nicole N   Mato Anthony A   Montillo Marco M   O'Brien Susan S   Dubowy Ronald R   Gu Lin L   Munugalavadla Veerendra V   Robak Tadeusz T   Hillmen Peter P  

Leukemia 20200712 12

Similar Datasets

Unknown Idelalisib for the treatment of chronic lymphocytic leukemia.
| S-EPMC4003830 | biostudies-literature
Unknown Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
| S-EPMC4161365 | biostudies-literature
Unknown Idelalisib impairs T-cell-mediated immunity in chronic lymphocytic leukemia.
| S-EPMC6269319 | biostudies-literature
Unknown Transcriptional Modulation by Idelalisib Synergizes with Bendamustine in Chronic Lymphocytic Leukemia.
| S-EPMC6826782 | biostudies-literature
Unknown Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib.
| S-EPMC8269042 | biostudies-literature
Unknown Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
| S-EPMC4523214 | biostudies-literature
Unknown The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab.
| S-EPMC7214265 | biostudies-literature
Unknown The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemia.
| S-EPMC4802506 | biostudies-literature
Unknown Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.
| S-EPMC4123414 | biostudies-literature
Unknown Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.
| S-EPMC5922273 | biostudies-literature